drugset / Trial / NCT01132118

Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis

NCT01132118

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether hydroxychloroquine (HCQ) reduces insulin resistance in non-diabetic subjects with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that HCQ improves insulin sensitivity. The investigators will also use data from the trial to identify determinants of insulin resistance in RA. The investigators hypothesize that RA will be associated with an increased risk of insulin resistance and that independent risk factors for increased insulin resistance in RA include higher BMI, elevated acute phase reactants, greater fat to muscle ratio, and less physical activity.

Timeline

Start
2010-06
Primary completion
2012-04
Completion
2012-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 6.5 mg/kg Oral

Indications